Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.006 AUD | 0.00% | 0.00% | -45.45% |
05-14 | Bioxyne to Release Shares from Escrow; Shares Up 17% | MT |
05-14 | Bioxyne Subsidiary, CY Biopharma Enter Partnership to Advance Novel Psilocybin Therapies in Australia | MT |
Valuation
Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 32.01 | 11.52 | 6.401 | 17.92 | 7.682 | 38.03 |
Enterprise Value (EV) 1 | 28.7 | 9.755 | 4.701 | 16.32 | 5.514 | 34.75 |
P/E ratio | -22.4 x | -9 x | -10.8 x | -35 x | -30.1 x | -13.9 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 14.9 x | 5.23 x | 2.76 x | 8.13 x | 3.09 x | 7.17 x |
EV / Revenue | 13.3 x | 4.43 x | 2.02 x | 7.4 x | 2.22 x | 6.55 x |
EV / EBITDA | -22.5 x | -7.54 x | -15.6 x | -124 x | -38.9 x | -20.1 x |
EV / FCF | -18.8 x | -10 x | 20.4 x | 34.5 x | 12.4 x | -63.8 x |
FCF Yield | -5.32% | -9.95% | 4.9% | 2.9% | 8.05% | -1.57% |
Price to Book | 7.41 x | 3.73 x | 2.5 x | 9.53 x | 4.07 x | 2.51 x |
Nbr of stocks (in thousands) | 640,145 | 640,145 | 640,145 | 640,145 | 640,145 | 1,901,645 |
Reference price 2 | 0.0500 | 0.0180 | 0.0100 | 0.0280 | 0.0120 | 0.0200 |
Announcement Date | 18-09-27 | 19-09-30 | 20-09-30 | 21-09-30 | 22-09-30 | 23-09-29 |
Income Statement Evolution (Annual data)
Fiscal Period: Juni | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 2.151 | 2.202 | 2.322 | 2.204 | 2.485 | 5.305 |
EBITDA 1 | -1.275 | -1.293 | -0.3009 | -0.132 | -0.1416 | -1.726 |
EBIT 1 | -1.288 | -1.311 | -0.3257 | -0.1497 | -0.1525 | -1.836 |
Operating Margin | -59.87% | -59.54% | -14.03% | -6.79% | -6.14% | -34.6% |
Earnings before Tax (EBT) 1 | -1.312 | -1.266 | -0.5931 | -0.4957 | -0.2365 | -1.964 |
Net income 1 | -1.312 | -1.266 | -0.5931 | -0.4957 | -0.2365 | -1.94 |
Net margin | -60.98% | -57.48% | -25.55% | -22.49% | -9.52% | -36.57% |
EPS 2 | -0.002231 | -0.002000 | -0.000926 | -0.000799 | -0.000399 | -0.001443 |
Free Cash Flow 1 | -1.526 | -0.9711 | 0.2305 | 0.4728 | 0.4436 | -0.5448 |
FCF margin | -70.92% | -44.09% | 9.93% | 21.45% | 17.85% | -10.27% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 18-09-27 | 19-09-30 | 20-09-30 | 21-09-30 | 22-09-30 | 23-09-29 |
Balance Sheet Analysis
Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 3.31 | 1.77 | 1.7 | 1.6 | 2.17 | 3.29 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -1.53 | -0.97 | 0.23 | 0.47 | 0.44 | -0.54 |
ROE (net income / shareholders' equity) | -31% | -33.9% | -20.6% | -21.8% | -12.2% | -26.8% |
ROA (Net income/ Total Assets) | -16.4% | -18.2% | -5.57% | -3.11% | -3.4% | -12.7% |
Assets 1 | 7.977 | 6.968 | 10.64 | 15.93 | 6.951 | 15.34 |
Book Value Per Share 2 | 0.0100 | 0 | 0 | 0 | 0 | 0.0100 |
Cash Flow per Share 2 | 0.0100 | 0 | 0 | 0 | 0 | 0 |
Capex 1 | 0.17 | 0.06 | 0.03 | - | 0.01 | 0.06 |
Capex / Sales | 7.97% | 2.89% | 1.45% | - | 0.23% | 1.07% |
Announcement Date | 18-09-27 | 19-09-30 | 20-09-30 | 21-09-30 | 22-09-30 | 23-09-29 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-45.45% | 8.2M | |
+39.87% | 54.04B | |
+44.70% | 41.96B | |
-1.51% | 41.92B | |
-7.20% | 28.35B | |
+12.44% | 26.35B | |
-21.73% | 19B | |
+6.97% | 13B | |
+29.06% | 12.28B | |
+25.69% | 12.19B |
- Stock Market
- Equities
- BXN Stock
- Financials Bioxyne Limited